Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Research Study in Patients With Persistent Macular Edema Due to Diabetic Retinopathy, Retinal Vein Occlusion, Uveitis, or Irvine-Gass Syndrome
Brief Summary: The purpose of this clinical research study is to evaluate the safety and effectiveness of an investigational medication to treat macular edema that persists despite current treatment methods. Participants will be evaluated for improvement in vision and side effects.

Macular edema is a condition that affects the back of the eye (retina). It frequently occurs in people who have a history of diabetes, and is also associated with high blood pressure, uveitis, and previous eye surgery. The main symptom of macular edema is decreased vision, generally a blurring of central vision.

There are no direct costs to participants for assessments and treatment as defined in the study protocol. All candidates must be available for required scheduled visits during the trial's 6-month follow-up period. Although the disease called age-related macular degeneration (AMD) affects the same region of the eye as macular edema, they are not the same condition and AMD is not studied in this research trial.


Options:
A: Intervention Type: DRUG; Name: DEX PS DDS®; Assigned to Arm(s): N/A
B: Arm Label: Sham injection plus laser; Type: EXPERIMENTAL; Interventions: Behavioral: Sham injection, Procedure: Focal/grid laser | Arm Label: 0.5mg Ranibizumab plus laser; Type: EXPERIMENTAL; Interventions: Drug: Ranibizumab, Procedure: Focal/grid laser | Arm Label: 4-mg Triamcinolone Acetonide plus Laser; Type: ACTIVE_COMPARATOR; Interventions: Drug: Triamcinolone Acetonide, Procedure: Focal/grid laser | Intervention Type: DRUG; Name: Ranibizumab; Assigned to Arm(s): 0.5mg Ranibizumab plus laser | Intervention Type: DRUG; Name: Triamcinolone Acetonide; Assigned to Arm(s): 4-mg Triamcinolone Acetonide plus Laser | Intervention Type: BEHAVIORAL; Name: Sham injection; Assigned to Arm(s): Sham injection plus laser | Intervention Type: PROCEDURE; Name: Focal/grid laser; Assigned to Arm(s): 0.5mg Ranibizumab plus laser, 4-mg Triamcinolone Acetonide plus Laser, Sham injection plus laser
C: Arm Label: Dexamethasone 700 μg; Type: EXPERIMENTAL; Interventions: Drug: Dexamethasone | Arm Label: Dexamethasone 350 μg; Type: EXPERIMENTAL; Interventions: Drug: Dexamethasone | Arm Label: Sham; Type: SHAM_COMPARATOR; Interventions: Other: Sham | Intervention Type: DRUG; Name: Dexamethasone; Assigned to Arm(s): Dexamethasone 350 μg, Dexamethasone 700 μg | Intervention Type: OTHER; Name: Sham; Assigned to Arm(s): Sham
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Laser Photocoagulation | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Bevacizumab | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: Bevacizumab | Arm Label: 4; Type: EXPERIMENTAL; Interventions: Drug: Bevacizumab | Arm Label: 5; Type: EXPERIMENTAL; Interventions: Drug: Bevacizumab | Intervention Type: PROCEDURE; Name: Laser Photocoagulation; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): 4 | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): 5

Answer: A